Nigella Sativa for COVID-19: real-time analysis of all 4 studies

Home

Database of all nigella sativa COVID-19 studies. Submit updates/corrections.


Aug 15	Early	Koshak et al., Complementary Therapies in Medicine, doi:10.1016/j.ctim.2021.102769 (Peer Reviewed)	hosp., ↓74.7%, p=0.37	Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial
	Details RCT 183 mild COVID-19 outpatients in Saudi Arabia, 91 treated with Nigella Sativa, showing lower hospitalization and faster recovery with treatment. NCT04401202.
Aug 15	Details Source PDF Early treatment study Early treatment study
	Koshak et al., Complementary Therapies in Medicine, doi:10.1016/j.ctim.2021.102769 (Peer Reviewed)
	Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial
	RCT 183 mild COVID-19 outpatients in Saudi Arabia, 91 treated with Nigella Sativa, showing lower hospitalization and faster recovery with treatment. NCT04401202. risk of hospitalization, 74.7% lower, RR 0.25, p = 0.37, treatment 1 of 91 (1.1%), control 4 of 92 (4.3%). risk of no recovery, 42.7% lower, RR 0.57, p < 0.001, treatment 34 of 91 (37.4%), control 60 of 92 (65.2%). Koshak et al., 8/15/2021, Randomized Controlled Trial, Saudi Arabia, Middle East, peer-reviewed, 10 authors.
	Share Tweet Submit Corrections or Comments
Jul 23	Review	Shad et al., Clinical and Experimental Pharmacology and Physiology, doi:10.1111/1440-1681.13553 (Review) (Peer Reviewed)	review	The role of thymoquinone, a major constituent of Nigella sativa, in the treatment of inflammatory and infectious diseases
	Details Review of the pharmacological properties of nigella sativa and thymoquinone and application for a variety of diseases, focusing on recent studies of the anti-inflammatory and antiviral properties that are promising for diseases including ..
Jul 23	Details Source PDF Review Review
	Shad et al., Clinical and Experimental Pharmacology and Physiology, doi:10.1111/1440-1681.13553 (Review) (Peer Reviewed)
	The role of thymoquinone, a major constituent of Nigella sativa, in the treatment of inflammatory and infectious diseases
	Review of the pharmacological properties of nigella sativa and thymoquinone and application for a variety of diseases, focusing on recent studies of the anti-inflammatory and antiviral properties that are promising for diseases including COVID-19. Shad et al., 7/23/2021, peer-reviewed, 3 authors.
	Share Tweet Submit Corrections or Comments
Mar 12	In Silico	Duru et al., Bulletin of the National Research Centre, doi:10.1186/s42269-021-00517-x (Peer Reviewed)		In silico identification of compounds from Nigella sativa seed oil as potential inhibitors of SARS-CoV-2 targets
	Details In Silico study of compounds from Nigella Sativa oil. Authors identify component phytochemicals with gas chromatography-mass spectrometry and analyze binding affinity with SARS-CoV-2 targets. Caryophyllene oxide, α-bergamotene, and β-bisa..
Mar 12	Details Source PDF In Silico In Silico
	Duru et al., Bulletin of the National Research Centre, doi:10.1186/s42269-021-00517-x (Peer Reviewed)
	In silico identification of compounds from Nigella sativa seed oil as potential inhibitors of SARS-CoV-2 targets
	In Silico study of compounds from Nigella Sativa oil. Authors identify component phytochemicals with gas chromatography-mass spectrometry and analyze binding affinity with SARS-CoV-2 targets. Caryophyllene oxide, α-bergamotene, and β-bisabolene were identified as promising candidates for inhibition. Duru et al., 3/12/2021, peer-reviewed, 3 authors.
	Share Tweet Submit Corrections or Comments
Jan 31	Early	Al-Haidari et al., Indian Journal of Forensic Medicine & Toxicology, 15:3 (preprint 1/2021) (Peer Reviewed)	death, ↓95.8%, p=0.001	Clinical Trial of Black Seeds Against COVID – 19 in Kirkuk City / Iraq
	Details Open-label RCT with 419 patients in Iraq, 160 treated with Nigella Sativa, showing lower mortality and severe cases with treatment.
Jan 31	Details Source PDF Early treatment study Early treatment study
	Al-Haidari et al., Indian Journal of Forensic Medicine & Toxicology, 15:3 (preprint 1/2021) (Peer Reviewed)
	Clinical Trial of Black Seeds Against COVID – 19 in Kirkuk City / Iraq
	Open-label RCT with 419 patients in Iraq, 160 treated with Nigella Sativa, showing lower mortality and severe cases with treatment. risk of death, 95.8% lower, RR 0.04, p = 0.001, treatment 0 of 160 (0.0%), control 14 of 259 (5.4%), continuity correction due to zero event. risk of COVID-19 severe case, 92.6% lower, RR 0.07, p < 0.001, treatment 2 of 160 (1.2%), control 44 of 259 (17.0%). Al-Haidari et al., 1/31/2021, Randomized Controlled Trial, Iraq, Middle East, peer-reviewed, 3 authors.
	Share Tweet Submit Corrections or Comments
Nov 3 2020	Early	Ashraf et al., medRxiv, doi:10.1101/2020.10.30.20217364 (Preprint)	death, ↓81.9%, p=0.01	Honey and Nigella sativa against COVID-19 in Pakistan (HNS-COVID-PK): A multi-center placebo-controlled randomized clinical trial
	Details RCT with 157 patients treated with honey and nigella sativa, and 156 control patients, showing significantly faster recovery and viral clearance. NCT04347382.
Nov 3 2020	Details Source PDF Early treatment study Early treatment study
	Ashraf et al., medRxiv, doi:10.1101/2020.10.30.20217364 (Preprint)
	Honey and Nigella sativa against COVID-19 in Pakistan (HNS-COVID-PK): A multi-center placebo-controlled randomized clinical trial
	RCT with 157 patients treated with honey and nigella sativa, and 156 control patients, showing significantly faster recovery and viral clearance. NCT04347382. risk of death, 81.9% lower, RR 0.18, p = 0.01, treatment 2 of 157 (1.3%), control 11 of 156 (7.1%), all cases. risk of death, 67.1% lower, RR 0.33, p = 0.49, treatment 0 of 107 (0.0%), control 1 of 103 (1.0%), continuity correction due to zero event, moderate cases. risk of death, 78.8% lower, RR 0.21, p = 0.03, treatment 2 of 50 (4.0%), control 10 of 53 (18.9%), severe cases. risk of no recovery, 83.6% lower, RR 0.16, p < 0.001, treatment 107, control 103, moderate cases. risk of no recovery, 75.2% lower, RR 0.25, p < 0.001, treatment 50, control 53, severe cases. risk of no virological cure, 81.9% lower, RR 0.18, p < 0.001, treatment 107, control 103, moderate cases. risk of no virological cure, 76.9% lower, RR 0.23, p < 0.001, treatment 50, control 53, severe cases. Ashraf et al., 11/3/2020, Randomized Controlled Trial, Pakistan, South Asia, preprint, 48 authors, this trial uses multiple treatments in the treatment arm (combined with honey) - results of individual treatments may vary.
	Share Tweet Submit Corrections or Comments

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit